ABC | Volume 114, Nº3, Março 2020

Posicionamento Posicionamento Brasileiro sobre Hipertensão Arterial Resistente – 2020 Arq Bras Cardiol. 2020; 114(3):576-596 39. Breaux-ShropshireTL,JuddE,VucovichLA,ShropshireTS,SinghS.Doeshome blood pressure monitoring improve patient outcomes? A systematic review comparinghomeandambulatorybloodpressuremonitoringonbloodpressure controlandpatientoutcomes. IntegrBloodPressControl.2015;8:43-9. 40. Alessi A, Brandao AA, Coca A, Cordeiro AC, Nogueira AR, Diogenes de Magalhaes F, et al. First Brazilian position on resistant hypertension. Arq Bras Cardiol.2012;99(1):576-85. 41. Souza WKS, Jardim PCB, Brito LP, Araújo FA, Sousa ALL. Automedida da pressão arterial para o controle das cifras tensionais e para a adesão ao tratamento.ArqBrasCardiol.2012;98:(2)167-74. 42. Vamsi V, Golub A, Mija P, Fekete P, Findri F, Prkacin I. Central blood pressure and pulse wave velocity in patients with resistant hypertension. Signa Vitae. 2018;14(Suppl1):28-30. 43. Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. JHypertens.2001;19(11):2063-70. 44. de laSierraA,BanegasJR,OliverasA,GorostidiM,SeguraJ,de laCruzJJ,etal. Clinical differences between resistant hypertensives and patients treated and controlledwiththreeor lessdrugs. JHypertens.2012;30(6):1211-6. 45. Sim JJ, Bhandari SK, Shi J, Reynolds K, Calhoun DA, Kalantar-Zadeh K, et al. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled,uncontrolledresistant,andnonresistanthypertension.KidneyInt. 2015;88(3):622-32. 46. NilssonPM.HemodynamicAgingastheConsequenceofStructuralChanges AssociatedwithEarlyVascularAging (EVA).AgingDis.2014;5(2):109-13. 47. PapakatsikaS,StabouliS,AntzaC,KotsisV.EarlyVascularAging:ANewTarget forHypertensionTreatment.CurrPharmDes.2016;22(1):122-6. 48. BarbaroNR, de Araujo TM, Tanus-Santos JE, AnheGF, Fontana V, MorenoH. Vascular Damage in Resistant Hypertension: TNF-Alpha Inhibition Effects on EndothelialCells.BiomedRes Int.2015;2015:631594. 49. Barbaro NR, Fontana V, Modolo R, De Faria AP, Sabbatini AR, Fonseca FH, et al. Increased arterial stiffness in resistant hypertension is associated with inflammatorybiomarkers.BloodPressure.2015;24(1):7-13. 50. Camici GG, Savarese G, Akhmedov A, Luscher TF. Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease. Eur Heart J.2015;36(48):3392-403. 51. HarveyA,MontezanoAC,TouyzRM.Vascularbiologyofageing-Implications inhypertension. JMolCellCardiol.2015 Jun;83:112-21. 52. RizzoniD,AgabitiRoseiC,DeCiuceisC,SemeraroF,RizzoniM,DocchioF.New MethodstoStudytheMicrocirculation.AmJHypertens.2018;31(3):265-73. 53. Lehmann MV, Schmieder RE. Remodeling of retinal small arteries in hypertension.Am JHypertens.2011;24(12):1267-73. 54. CeceljaM,ChowienczykP.MolecularMechanismsofArterialStiffening.Pulse (Basel).2016;4(1):43-8. 55. Mikael LR, Paiva AMG, GomesMM, Sousa ALL, JardimP, Vitorino PVO, et al. VascularAgingandArterialStiffness.ArqBrasCardiol.2017;109(3):253-8. 56. Mozos I, Malainer C, Horbanczuk J, Gug C, Stoian D, Luca CT, et al. Inflammatory Markers for Arterial Stiffness in Cardiovascular Diseases. Front Immunol.2017;8:1058. 57. BalduinoMendesAB,Giollo-JuniorLT,deAndradeDO,GregorioML,Yugar- ToledoJC,Vilela-MartinJF.HowtoInvestigatetheVascularChangesinResistant Hypertension.CurrHypertensRev.2016;12(2):139-47. 58. Virdis A. Arterial Stiffness and Vascular Aging: From Pathophysiology to Treatment, with a Look at the Future. High Blood Press Cardiovasc Prev. 2018;25(2):135-6. 59. JolyL.Arterialstiffnessandcognitivefunction.GeriatrPsycholNeuropsychiatr Vieil.2017;15(1):83-8. 60. Hughes TM,Wagenknecht LE, Craft S, Mintz A, Heiss G, Palta P, et al. Arterial stiffnessanddementiapathology:AtherosclerosisRiskinCommunities(ARIC)- PETStudy.Neurology.2018;90(14):e1248-e56. 61. Muntner P, Davis BR, CushmanWC, Bangalore S, Calhoun DA, Pressel SL, et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-LoweringTreatmenttoPreventHeartAttackTrial(ALLHAT).Hypertension. 2014;64(5):1012-21. 62. LotufoPA,PereiraAC,VasconcellosPS,SantosIS,MillJG,BensenorIM.Resistant Hypertension:RiskFactors,SubclinicalAtherosclerosis,andComorbiditiesAmong Adults—The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). J Clin Hypertens.2015;17(1):74-80. 63. IadecolaC.HypertensionandDementia.Hypertension.2014;64(1):3-5. 64. LaurentS,BoutouyrieP.Thestructuralfactorofhypertension:largeandsmallartery alterations.CircRes.2015;116(6):1007-21. 65. HowardVJ,TannerRM,AndersonA,IrvinMR,CalhounDA,LacklandDT,etal. Apparent Treatment-resistant Hypertension Among Individuals withHistory of StrokeorTransientIschemicAttack.AmJMed.2015;128(7):707-14.e2. 66. Hong J-H, Sohn S-I, Kwak J, Yoo J, Ahn SJ,Woo SJ, et al. Retinal artery occlusion and associated recurrent vascular risk with underlying etiologies. PLoS One. 2017;12(6):e0177663. 67. HongD,StradlingD,DasturCK,AkbariY,GroysmanL,Al-KhouryL,etal.Resistant Hypertension after Hypertensive Intracerebral Hemorrhage Is Associated withMoreMedical Interventions and Longer Hospital Stays without Affecting Outcome.FrontNeurol.2017;8:184. 68. ChenY,ShenF,LiuJ,YangGY.Arterialstiffnessandstroke:de-stiffeningstrategy,a therapeutictargetforstroke.StrokeVascNeurol.2017;2(2):65-72. 69. CuspidiC,VaccarellaA,NegriF,SalaC.Resistanthypertensionandleftventricular h ypertrophy:anoverview.JAmSocHypertens. 2010;4(6):319-24. 70. Nadruz W. Myocardial remodeling in hypertension. J Hum Hypertens. 2015;29(1):1-6. 71. Muxfeldt ES, Salles GF. Pulse pressure or dipping pattern: which one is a better cardiovascular risk marker in resistant hypertension? J Hypertens. 2008;26(5):878-84. 72. ModoloR,deFariaAP,PaganelliMO,SabbatiniAR,BarbaroNR,NascimentoBB, et al. Predictors of silent myocardial ischemia in resistant hypertensive patients. AmJHypertens.2015;28(2):200-7. 73. Muxfeldt ES, de Souza F, Margallo VS, Salles GF. Cardiovascular and renal complications in patients with resistant hypertension. Curr Hypertens Rep. 2014;16(9):471. 74. NadruzW,ShahAM,SolomonSD.DiastolicDysfunctionandHypertension.Med ClinNorthAm.2017;101(1):7-17. 75. Rodrigues CIS CR, Almeida FA. Hipertensao arterial resistente. In: Moura LRR,AlvesMAR,SantosDR,PecoitsFilhoR.TratadodeNefrologia.SãoPaulo: Atheneu;2018. 76. SummaryofRecommendationStatements.KidneyIntSuppl.2013;3(1):5-14. 77. TalerSJ,TextorSC,AugustineJE.Resistanthypertension:comparinghemodynamic managementtospecialistcare.Hypertension.2002;39(5):982-8. 78. GaddamKK, NishizakaMK, Pratt-UbunamaMN, Pimenta E, Aban I, Oparil S, et al. Characterization of resistant hypertension: association between resistant hypertension,aldosterone,andpersistentintravascularvolumeexpansion.Arch InternMed.2008;168(11):1159-64. 79. Pimenta E, GaddamKK, Oparil S, Aban I, Husain S, Dell'Italia LJ, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hy pertension:resultsfromarandomizedtrial.Hypertension .2009;54(3):475-81. 80. Agarwal R. Resistant hypertension and the neglected antihypertensive: sodium restriction.NephrolDialTransplant.2012;27(11):4041-5. 81. Shimosawa T. Salt, the renin-angiotensin-aldosterone system and resistant hypertension.HypertensRes.2013;36(8):657-60. 82. CalhounDA.RefractoryandResistantHypertension:AntihypertensiveTreatment FailureversusTreatmentResistance.KoreanCircJ.2016;46(5):593-600. 83. Eirin A, Textor SC, Lerman LO. Emerging concepts for patients with treatment- resistanthypertension.TrendsCardiovascMed.2016;26(8):700-6. 593